1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsACBS provides three Research Development Grants, with one reserved for qualifying projects for researchers living/working in "Low-Income Economies" or “Lower-Middle Income Economies” or “Upper-Middle Income Economies” as defined by World Bank Country and Lending Groups.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Researchers living/working in "Low-Income Economies" or “Lower-Middle Income Economies” or “Upper-Middle Income Economies” as defined by World Bank Country and Lending Groups. Confirm the full requirements in the official notice before applying.
The current listing shows up to $5,000 USD. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Research Development Grants is funded by ACBS Foundation (Association for Contextual Behavioral Science). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Merck Stimulating Innovative Research Grant Program 2026 includes a dedicated grant topic for artificial intelligence in cell culture media and process development, offering up to EUR 150,000 per year for up to 3 years. The program accelerates innovation through collaborative research, early engagement with industry experts, and translation of novel ideas into practical solutions. In 2026, priority areas also include in-vitro models for neuroinflammatory diseases (EUR 250,000/year for 2 years) and innovative approaches to contaminated materials remediation (EUR 150,000/year for 2 years). The two-stage application process begins with non-confidential submissions, followed by deep-dive workshops where finalists collaborate with Merck scientists and managers to jointly optimize proposals. The AI-specific grant focuses on applying machine learning and AI to optimize cell culture media formulation, bioprocess parameter optimization, and manufacturing quality control.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
On August 26, 2026, NSF named the STC class of 2026: TEMPEST at Michigan State, GENIE at Northwestern, and a human-robot co-adaptation center at UT Austin. $90 million total, $6 million a year each. The 2023 class was four centers and $120 million. The award size is intact; the shelf space shrank 25 percent — and that is the number that should reshape how you plan a center proposal.
Read articleNIH published its 'what we heard' summary on the proposed cap on simultaneous Research Project Grants in August 2026. A four-RPG cap would free $1.3 billion for about 1,900 additional investigators; a two-RPG cap would free roughly $3.5 billion for about 5,200. Respondents overwhelmingly proposed alternatives. Here is what the comment record actually says, what NIH signaled about next steps, and how PIs and research offices should position before a policy notice lands.
Read articleBJA opened five FY2026 competitions covering reentry, family-based substance use treatment, opioid response and crisis stabilization, with award ceilings from $1 million to $3 million. Grants.gov closes September 24 and 25; JustGrants closes October 1 and 2. The seven-day gap between them is the single most common reason a finished DOJ application never gets reviewed.
Read article